secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001193125-24-139476
Event type: leadership
Sentiment:  negative
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Aligos Therapeutics Chief Medical Officer Matthew McClure resigns effective May 9, 2024
--------------------------------------------------------------------------------

- Matthew McClure resigned as Chief Medical Officer on May 9, 2024.
- No replacement or interim CMO was announced in the filing.
- The departure follows Aligos's focus on antiviral therapeutics; impact on pipeline unclear.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000119312524139476/0001193125-24-139476-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000119312524139476/d793808d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-139476

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer